RegImmune, Inc.: Series B $4.2M

RegImmune (Mountain View, CA) technology platform named reVax is targeting various allergic and immune diseases, with lead indications in allergies and organ rejection has raised a $4.2M Series B round. The deal was lead by NIF SMBC Ventures Co. Ltd. and was joined by Japan Asia Investment Co. Ltd., JAFCO Co. Ltd., Orix Capital Corporation, Yasuda Enterprise Development Co. Ltd., New Business Investment Co. Ltd., Mitsubishi UFJ Capital Co. Ltd., and Fund Creation Co. Ltd..

Trellis Bioscience, Inc.: Series B $10M

Trellis Bioscience (San Francisco, CA) developer of therapeutic monoclonal antibody drug development platform raised $10M in Series B funding. The round was led by Novartis Bioventures along with Pac-Link Bio Venture, Sagamore Bioventures, Easton-Hunt Capital Partners and Morgenthaler Partners.

Locus Pharma, Inc.: Series D $30.2M

Locus Pharma (Blue Bell, PA) is focused on the development of novel small molecule drug therapies raised a $30.2M Series D financing. The round was led by Novartis Bioventures, Prism Venture Partners and HBM BioVentures. Other participants included S.R. One Capital and L Capital Partners.

4-Antibody AG: Series A $18.5M

4-Antibody (Basel, Switzerland) a biopharmaceutical company developing optimal therapeutic antibody drugs has raised around $13.7M in additional Series A funding, bringing the round total to $18.5 million. The round was led by Advent Venture Partners and was joined by existing backers Life Sciences Partners, BioMedinvest AG, Grazia Equity and Mulligan Biocapital.